|
Jan 2
|
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Dec 31
|
Wedbush starts Rocket Pharmaceuticals with Outperform into ‘inflection year’
|
|
Dec 30
|
Rocket Pharmaceuticals' Continued Pipeline Development to Support Long-Term Growth Potential, Wedbush Says
|
|
Dec 29
|
Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now?
|
|
Sep 10
|
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
|
|
Sep 9
|
Rocket Stock Down More Than 30% in Past Six Months: Here's Why
|
|
Aug 25
|
Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks
|
|
May 10
|
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
|
|
May 7
|
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
|
|
May 6
|
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
|
|
Apr 30
|
Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why
|
|
Apr 24
|
Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)?
|
|
Apr 3
|
EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia
|
|
Apr 2
|
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
|
|
Mar 27
|
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
|
|
Mar 26
|
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
|
|
Dec 15
|
11 Most Promising Biotech Stocks to Buy According to Analysts
|
|
Dec 12
|
Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
|
|
Nov 6
|
Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
|
|
Nov 5
|
With This Rally, Rocket Just Might Take Off
|